Treatment, outcomes, and resource utilization among patients with metastatic breast and advanced epithelial ovarian cancer, by BRCA1/2 and HRD status
This study demonstrated differences in treatment by BRCA1/2 and HRD status. There was low PARPi uptake among patients with BRCA-mutated mBC but not among patients with aEOC. In aEOC, the cost to "treat all" may outweigh benefits; identifying patients without HRD likely to benefit from PARPis is needed.
Authors
- Liam C. Lee
- Henry G. Kaplan (ORCID: https://orcid.org/0000-0001-9866-5200)
- Giovanna Cruz (ORCID: https://orcid.org/0000-0001-7422-6043)
- Charles W. Drescher (ORCID: https://orcid.org/0000-0002-6579-0416)
- Connor Sweetnam (ORCID: https://orcid.org/0000-0002-4275-0569)
- Monika A. Izano (ORCID: https://orcid.org/0000-0003-1852-5342)
- Gieira S. Jones (ORCID: https://orcid.org/0000-0001-9537-6470)
- Arthur Sillah (ORCID: https://orcid.org/0000-0003-1065-6735)
- A. Williams (ORCID: https://orcid.org/0000-0002-9542-1769)
- Liz Toland
- Jagadeswara Rao Earla (ORCID: https://orcid.org/0000-0002-6688-5273)
- Rayna K. Matsuno (ORCID: https://orcid.org/0000-0002-0426-9950)
- Kaitlyn Kane
- Amy L. Stone (ORCID: https://orcid.org/0000-0003-3153-151X)
- Smita Kothari (ORCID: https://orcid.org/0000-0001-5614-3332)
- Anna B. Berry (ORCID: https://orcid.org/0000-0002-9246-4560)
- Thomas D. Brown (ORCID: https://orcid.org/0000-0002-2123-1014)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Swedish Medical Center (US)
- Swedish Medical Center (US)
- Chester County Historical Society (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1093/oncolo/oyaf100
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05